Jade Whiting – Argenica Therapeutics

2026

17 Mar 2026Argenica boosts cash reserves with $3.97m R&D rebate to advance stroke drug
17 Mar 2026Argenica Lands $3.97M Tax Rebate, Lifting Cash to $9M Without DilutionReference: StockWireX
17 Mar 2026Argenica’s $3.97M Rebate Raises Stakes for Upcoming Stroke Trial SuccessReference: Middle.
19 Feb 2026Overcoming Operational Hurdles in a High-Stakes Stroke TrialReference: ProPharma
18 Feb 2026Sophisticated AI analysis reveals efficacy of neuroprotective drug for severe strokeReference: Perron Institute
03 Feb 2026EMA Clears Regulatory Path for Argenica’s ARG-007 Stroke TrialsReference: Brief Pharma
02 Feb 2026Argenica Wins EMA Paediatric Waiver Clearing ARG-007 European Approval PathReference: https://stockwirex.com/asx-stock-news/biotech-health/agn-argenica-therapeutics-ema-paediatric-waiver-february-2025/
02 Feb 2026Waiver Removes Paediatric Trials, But Will ARG-007 Face Other Regulatory Hurdles?Reference: Middle.
02 Feb 2026What emerging technologies or scientific breakthroughs do you believe will most reshape biopharma in the next 10 years?Reference: Pharma's Almanac
28 Jan 2026ARG-007 Shows Statistically Significant Stroke Recovery Gains in Phase 2 TrialReference: Middle.